US Tech Transfer Blooms For BMS Under Allied Minds JV
Bristol-Myers Squibb Co. entered a joint venture two years ago with US IP commercialization firm Allied Minds to identify innovation from US universities and research institutions. The project is beginning to bear fruit, and the JV has now secured $100m to fund up to 10 promising drug development opportunities. Allied Minds CEO Chris Silva talks to Scrip's Sukaina Virji about what happens next.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.